Introduction
HIV-1-infected controllers comprise a small fraction (<1%) of HIV-1-infected individuals that maintain continuous control over viral replication without the need of antiretroviral therapy [1, 2] . Controllers have generally been defined as either having undetectable HIV-1 RNA levels using conventional assays (e.g. below 50 copies RNA/ml; 'elite controllers') or having low but detectable levels of viral replication (e.g. 50-2000 copies RNA/ml; 'viremic controllers') [3] . Although controllers cannot eradicate HIV-1 from the body, they represent the highest echelon of immune control exhibited by infected patients over HIV-1 replication. Consequently, the nature of the protective immune response in controllers is of considerable interest.
Host factors identified in HIV-1-infected controller individuals include cellular proteins that limit viral entry or replication within CD4 target cells [4, 5] . Nonhost factors associated with HIV-1-infected controller status include the reduced replicative capacity of viruses from some controller individuals [6] [7] [8] [9] . Immunologically, recent data indicate that CD8 þ T-cell responses directed against the HIV-1 Gag protein are heightened in some controllers [10] [11] [12] , as are effector molecules important for cytotoxic T lymphocyte (CTL) activity such as T-bet and perforin [13, 14] . Likewise, protective major histocompatibility complex (MHC) class I (MHC-1) alleles important for CD8 þ T-cell recognition of target cells [such as human leukocyte antigen (HLA-B Ã 57)] are positively correlated with delayed progression to AIDS [15] [16] [17] [18] and enriched in HIV-1 controller cohorts [10, 12] . Together, these studies highlight a role for the adaptive T-cell response in maintaining low viral loads among controller individuals. However, immunological heterogeneity has been observed among individuals in HIV-1 controllers cohorts, with greater than half of HIV-1 controllers lacking protective T-cell HLA-B alleles or exhibiting low to undetectable HIV-specific CD8 T-cell responses [10, 12] . This latter data suggest that alternative mechanisms of immune control, such as innate immune (natural killer, NK) effector responses, may also contribute to sustained viral control along with traditional adaptive immune responses in some controller individuals.
More recent data have shown a consistent association between certain NK cell killer inhibitory receptor (KIR) alleles and virus control, suggesting that NK cells may also have a functional role in controlling HIV replication [19, 20] . Inheritance of a KIR3DL1 inhibitory receptor genotype that exhibits high cell surface expression (KIR3DL1 Ã h) is associated with delayed progression to AIDS when co-inherited with its corresponding HLA-Bw4 Ã 80I ligand [21] . Similarly, KIR3DS1, an activating allele of the same locus, has also been associated with delayed progression to AIDS in conjunction with HLA-B alleles [22] . Inheritance of protective KIR3DL1 Ã h/ Ã y receptor genes along with their corresponding HLA-Bw4 Ã 80I ligands is believed to lead to high cell surface expression and strong NK licensing [23] , whereas NK cells expressing KIR3DS1 have been shown to produce more interferon-g (IFNg) [24] and mediate stronger inhibition of HIV-1 replication [25] .
In addition to serving a protective HLA allele, HLA-B Ã 57 serves as one of the strongest ligands for the KIR3DL1 family of receptors [19, 26] . The combined genotype of HLA-B Ã 57 with KIR3DL1 Ã h/ Ã y confers more protection from HIV-1 disease progression than either genotype alone, suggesting that a synergistic response between the adaptive and innate immune compartment may work in concert to limit viral replication [20, 21] . However, a comparative analysis of the genotype and function of the innate and adaptive immune compartments in HIV-1-infected controller individuals has been understudied to date. We hypothesized that increased NK activity may account for the sustained control over viral replication in a subset of controllers with protective KIR3DL1 alleles but lacking strong HIV-1-specific CD8 þ T-cell responses. In support of this hypothesis, we observed a significant inverse association between the IFNa-stimulated NK response to K562 cells and the HIV-specific CD8 T-cell response to Gag among elite controllers. Specifically, the inheritance of protective KIR3DL1 Ã h/ Ã y receptor genotype associated with strong NK responses was significantly correlated with a decrease in HIV-1 Gagspecific CD8 responses among elite controllers. Together, these results indicate that heightened NK responses following stimulation can be evidenced independently of HIV-specific T-cell responses in HIV-1-infected controllers that limit viral replication naturally.
Materials and methods
Individual criteria and clinical assessment HIV-infected adults were sampled from the University of California, San Francisco (San Francisco, California, USA)-based Study of Consequences to Protease Inhibitor Era (SCOPE) cohort and whole blood was shipped overnight to the Wistar Institute, Philadelphia, Pennsylvania, USA by air courier for analysis. Samples were properly insulated and quality control was maintained to ensure the viability and functional output of innate and adaptive immune cells from all individuals as previously described [27] . Controllers were defined as HIV-seropositive individuals who were not receiving antiretroviral therapy and who had either undetectable HIV-1 RNA levels using conventional assays (<50 copies/ml by Abbott RealTime PCR or <75 copies/ml by branched DNA testing; 'elite controllers') or low but detectable levels of viral replication (e.g. 50-2000 copies RNA/ml; 'viremic controllers') for a minimum of 5 years (Table 1 ). Isolated episodes of viremia above these thresholds were allowed. All participants provided informed consent, and this research was approved by the Institutional Review Board of the University of California San Francisco, the National Institutes of Health (NIH) and the Wistar Institute.
Allele genotyping
Participating elite and viremic controller individuals recruited from the University of California, San Francisco-based SCOPE cohort were selected based upon previous genotyping for protective HLA and KIR3DL1 Ã h/ Ã y genotypes conducted at the Immunogenetics Laboratory in the National Cancer Institute. Briefly, 2 Â 10 6 peripheral blood mononuclear cells (PBMCs) from HIV-1-infected controllers were frozen in DNAzol (Molecular Research Center, Cincinnati, Ohio, USA) and genotyped as previously described [28] . The HLA class I loci were typed by the sequence-based typing method as recommended by the 13th International Histo-compatibility Workshop (http://www.ihwg.org/ tmanual/TMcontents.htm). We defined the following HLA-B alleles (HLA-B Ã 13, HLA-B Ã 2705, HLA-B Ã 57, HLA-B Ã 5801, HLA-B Ã 8100) as protective as shown in Supplementary Table 1 (http://links.lww.com/QAD/ A248) based upon previous studies highlighting their association with lower viral loads and increased frequency in HIV-1 controller cohorts [10, 12] .
The protective NK KIR3DL1 receptor genotype was defined as described previously [21, 29] and referred to as KIR3DL1 Ã h/ Ã y (Supplementary Table 1 , http://links. lww.com/QAD/A248). Corresponding ligands for the KIR3DL1 receptor were identified among HLA-B or HLA-A alleles with isoleucine at amino acid position 80 as previously described [22, 30] . Only controllers possessing a KIR3DL1 Ã h/ Ã y genotype in conjunction with their corresponding HLA-Bw4 Ã 80I ligands were defined as possessing protective KIR3DL1 genotype and were compared with controllers lacking either the KIR3DL1 Ã h/ Ã y genotype or the requisite HLA-Bw4 Ã 80I ligands. Due to their low frequency and potentially confounding effects, individuals inheriting the KIR3DS1 activating receptor were excluded from the analysis.
Flow cytometry
All cell surface antibodies and isotype controls were preconjugated and used at the recommended dilution of 0.25-mg antibody per million cells in PBSA (PBS with 0.09% sodium azide). PBMCs were stained with antibodies to phenotypic and functional markers for 15 min at room temperature in the dark and washed twice. Cells were then fixed and permeabilized with the Cytofix/Cytoperm kit (BD Biosciences, San Jose, California, USA) as described by the manufacturer. Intracellular staining was carried out in 1Â Perm/Wash Buffer (BD Biosciences) for 15 min at room temperature in the dark with 0.25 mg of anti-IFNg FITC antibody (BD Biosciences) per million cells. A minimum of 1 00 000 events were collected on a BD LSR-II Flow Cytometer (BD Biosciences) and samples were subsequently analyzed with FlowJo software (Tree Star Incorporated, Ashland, Oregon, USA). Prior to analysis, all samples were gated by forward (height and area) and side-scatter to exclude doublets and dead cells.
Natural killer target cell degranulation and intracellular cytokine staining assay Samples comprising 0.5 Â 10 6 PBMCs were cocultured alone (no target control) or with K562 cells at a 10 : 1 effector-to-target ratio in the presence of 10-ml anti-CD107a monoclonal antibody, 0.133-ml Golgi-stop (BD Biosciences) and 5-mg/ml Brefeldin A (BD Biosciences) for 4 h in a 200 ml volume. PBMCs were washed, stained with antibodies to NK cell phenotypic markers (CD56/ CD3) and intracellular staining for IFNg was carried out as described above. NK cells were gated by CD56 þ / CD3 À expression and the percentage of NK cells staining positive for CD107a and/or IFNg following incubation with K562 cells was determined after subtraction of background levels of staining in the absence of target cells.
T-cell peptide stimulation and intracellular cytokine staining assay
Samples comprising 0.5 Â 10 6 PBMCs were cocultured with a 1 mg/ml mixture of overlapping 15-mer peptides spanning the HIV-1 consensus clade B Gag protein (AIDS Research and Reference Reagent Repository, NIH) in the presence of 2.5-ml CD28/CD49d costimulation (BD Biosciences) and 5-mg/ml Brefeldin A for 18 h in a 200 ml volume. Alternatively, PBMCs were stimulated with a 1 mg/ml mixture of a CEF peptide pool comprising 23 peptides consisting of sequences derived from the human cytomegalovirus (CMV), Epstein-Barr (EBV) and influenza viruses (AIDS Research and Reference Reagent Repository, NIH). Unstimulated and 5-mg/ml staphylococcal enterotoxin B (SEB, Sigma Aldrich)-stimulated PBMCs were used as negative and positive controls, respectively. PBMCs were washed, stained with antibodies to T-cell phenotypic markers (CD8/CD3) and intracellular staining for IFNg was carried out as described above. CD8 T cells were gated by CD8 þ /CD3 þ staining and the percentage of cells staining positive for CD107a and/or IFNg was determined after subtraction of background levels of staining in unstimulated control cells. 
Statistical analysis
All graphic presentations and statistical analyses were performed with Prism software (GraphPad Software, La Jolla, California, USA). Statistical analysis of two groups was carried out using a Mann-Whitney unpaired, nonparametric t-test and graphic comparisons are displayed as median with interquartile range. Correlations between two variables were carried out using a nonparametric Spearman correlation of untransformed data with a 95% confidence interval. In all cases, P values were two-sided with alpha less than 0.05.
Results
Protective human leukocyte antigen and killer inhibitory receptor genotypes in elite and viremic controllers To investigate the role of protective HLA and KIR genotypes in influencing innate and adaptive immune function, we utilized a well characterized cohort of HIV-1-infected controllers [10] . This cohort was comprised of 14 elite controllers and 23 viremic controllers that exhibited a mean duration of infection of over 20 years without the need for antiretroviral therapy ( Table 1) . As documented previously among HIV-1 controller cohorts [10, 12] , we observed a pronounced enrichment of protective HLA-B alleles associated with delayed progression to AIDS among both viremic and elite controllers in our study (data not shown). Similarly, we confirmed that both viremic and elite controllers exhibited a high frequency of protective KIR3DL1 Ã h/ Ã y receptor genotypes associated with delayed progression to AIDS [21] (data not shown).
To investigate the impact of protective HLA and KIR3DL1 Ã h/ Ã y genotypes on predicting innate and adaptive immune function among elite and viremic controllers, we recruited individuals based upon the presence or absence of protective T-cell HLA-B alleles and protective NK KIR3DL1 Ã h/ Ã y genotypes as described in the Materials and Methods and shown in Supplementary Table 1 (http://links.lww.com/QAD/A248).
Influence of KIR3DL1Mh/My receptor genotype on natural killer activity in controllers
First, we measured whether target cell-induced NK functional activity was correlated with the inheritance of protective KIR3DL1 Ã h/ Ã y receptor genotypes and their corresponding HLA-Bw4 Ã 80I ligands. As we documented previously [31] , we observed that NK cell CD107a degranulation and IFNg cytokine production in response to K562 tumor cells was dramatically increased in the presence of IFNa stimulation (Fig. 1a ). Following IFNa stimulation of PBMCs, NK function against K562 target cells was significantly augmented (P¼0.0201) in controllers possessing a protective KIR3DL1 Ã h/ Ã y receptor genotype along with their corresponding HLA-Bw4 Ã 80I ligand (Fig. 1c) . The functional capacity of IFNa-stimulated NK cells from individuals inheriting the KIR3DL1 Ã h/ Ã y genotype in conjunction with their corresponding HLA-Bw4 Ã 80I ligands was significantly increased compared with controllers lacking either the protective KIR3DL1 Ã h/ Ã y genotype or the requisite HLA-Bw4 Ã 80I ligand ( Supplementary Figure 1 , http:// links.lww.com/QAD/A248). In unstimulated PBMCs, the enhanced functional output of NK cells from controllers possessing a protective KIR3DL1 Ã h/ Ã y receptor genotype along with their corresponding HLA-Bw4 Ã 80I ligand was also observed, but the effect was not statistically significant (Fig. 1b) . These findings suggest that target cell-induced NK functional activity following IFNa stimulation was correlated with the inheritance of protective KIR3DL1 Ã h/ Ã y receptor genotypes and their corresponding HLA-Bw4 Ã 80I ligands.
NK cell frequency was similar between controllers possessing or lacking the KIR3DL1 Ã h/ Ã y receptor genotype along with their corresponding HLA-Bw4 Ã 80I 80I ligand (data not shown), and NK frequency within the PBMCs was not correlated with NK functional output ( Fig. 1d ). Although high viral loads have been shown to inversely impact NK function [32] [33] [34] , we did not observe that NK function was negatively impacted by low levels of viral replication (Fig. 1e) . Similarly, the NK response to K562 cells among elite controllers and viremic controllers possessing the protective KIR3DL1 Ã h/ Ã y receptor genotypes and their corresponding HLA-Bw4 Ã 80I ligands was comparable (data not shown). This data indicate that the heightened NK response among both elite and viremic controllers inheriting protective NK receptor genotypes is maintained in HIV-1-infected individuals exhibiting either total or partial control over viral replication in contrast to the loss of function expected in noncontrollers with higher levels of viral replication.
Influence of protective HLA-B alleles on HIV-1 Gag-specific T-cell responses among controllers
To characterize the role of protective HLA-B alleles in predicting T-cell function in controllers, we measured the capacity of CD8 þ /CD3 þ gated T cells from fresh PBMCs to produce IFNg or degranulate in response to HIV-1 peptide pools ( Fig. 2a ). We focused on HIV-1 Gag-specific T cells responses due to their enhanced functional activity [35] and pronounced effect on reducing viral load among HIV-1 infected individuals [36] . As shown in Fig. 2b , there was a wide heterogeneity in Gag-specific CD8 þ T-cell responses among controllers with some individuals exhibiting low or undetectable Gag-specific responses and others exhibiting very high levels. However, Gagspecific CD8 þ T-cell responses were not significantly different between controllers possessing or lacking protective HLA-B alleles (Fig. 2B ). SEB-specific and CEFspecific (CMV, EBV and flu) CD8 þ T-cell responses also did not differ between controllers possessing or lacking protective HLA alleles (data not shown). There was an increased trend in Gag-specific CD8 þ T-cell responses in viremic controllers versus elite controllers (data not shown), potentially due to the effect of a low level of viral replication on stimulating Gag-specific CD8 þ recall responses. However, no significant correlation between viral load and the frequency of Gag-specific responses was observed (Fig. 2c ).
Inverse relationship between T-cell and natural killer cell activity among elite controllers
Due to the observed heterogeneity in T-cell responses among controllers (Fig. 2b ), we hypothesized that increased NK activity may account for the sustained control over viral replication in a subset of controllers Spearman correlation of IFNa-induced K562-specific NK function as described in panel B (y-axis) and NK frequency (d) or the log-viral load (e) (x-axis). Comparisons between two groups were performed using an unpaired, nonparametric Mann-Whitney t-test and correlations between two variables were carried out using a nonparametric Spearman test. In all cases, P values were two-tailed with a 95% confidence interval.
lacking strong HIV-1-specific CD8 þ T-cell responses. Due to the potential confounding effect of viral replication on HIV-specific T-cell responses in viremic controllers, we focused exclusively on elite controllers. As shown in Fig. 3a , we observed that elite controllers possessing low HIV-1-specific CD8 þ T-cell responses (x-axis) did indeed possess heightened IFNa-induced NK responses against K562 target cells (y-axis). The inverse association between HIV-1-specific CD8 þ T-cell responses and NK activity was significant (rho ¼ À0.8321, P ¼ 0.001, n ¼ 12), and was not observed when NK activity was plotted against CEF-specific CD8 þ T-cell responses against the combined epitopes of CMV, EBV and flu (Fig. 3b ). Finally, we tested if the observed inverse association between HIV-1-specific CD8 þ T-cell responses and NK activity was due to inheritance patterns in protective KIR3DL1 Ã h/ Ã y genotypes. As shown in Fig. 3c , elite controllers that possessed protective KIR3DL1 Ã h/ Ã y alleles along with their corresponding HLA-Bw4 Ã 80I alleles had significantly lower (P ¼ 0.0087) CD8 responses to HIV-1 Gag than controllers lacking protective KIR3DL1 Ã h/ Ã y alleles. Importantly, prestimulation with IFNa does not alter the absolute number of CD8 þ cells nor the frequency of HIV-specific CD8 þ T cells (Supplemental Figure 2 , http://links.lww.com/QAD/A248), consistent with the innate immune responses being the primary effector response activated by IFNa. Together, these results suggest that inheritance patterns of protective KIR3DL1 Ã h/ Ã y genotypes may influence the magnitude of both antiviral NK cell and CD8 T-cell responses among elite controllers.
Discussion
Here, we simultaneously tested the functional capacity of both NK cells and T cells in HIV-1-infected controller individuals to investigate correlates of immune control over viral replication. We hypothesized that increased NK activity may account for the sustained control over viral Comparisons between two groups were performed using an unpaired, nonparametric Mann-Whitney T-test and correlations between two variables were carried out using a nonparametric Spearman test. In all cases, P values were two-tailed with a 95% confidence interval.
replication in a subset of controllers lacking strong HIV-1-specific CD8 þ T-cell responses. In support of this hypothesis, we observed a significant inverse association between the IFNa stimulated NK response to K562 cells and the HIV-specific CD8 T-cell response to Gag among elite controllers (Fig. 3a) . The inheritance of protective KIR3DL1 Ã h/ Ã y receptor genotype previously associated with strong NK responses was also associated with a statistically significant decrease in HIV-1 Gag-specific CD8 responses among elite controllers (Fig. 3c) . These findings suggest that NK responses and T-cell responses can be observed independently in HIV-1-infected controllers, and that inheritance of protective NK cell KIR3DL1 Ã h/ Ã y genotypes may influence the magnitude of both antiviral NK cell and CD8 þ T-cell responses. Interestingly, a negative regulatory role of NK cells on antiviral CD8 þ T cells was recently described by Waggoner et al. [37] , and this is the first observation of a similar relationship between NK function and CD8 activity in HIV-1-infected elite controllers.
Importantly, we documented that both NK cells and CD8 þ T cells from controllers exhibit strong effector function when tested in vitro despite detectable levels of viremia in most controller individuals ( Figs. 1 and 2 ). High levels of viremia have been shown to negatively impact NK function [32] [33] [34] ; however, we did not observe that NK activity was inversely affected by the lower viral loads exhibited by controllers from our cohort (Fig. 1e ). NK cells from controllers also remained responsive to IFNa stimulation, which has been shown to be necessary for NK-mediated lysis against several virally infected target cell types including herpes virus-infected fibroblasts [38] [39] [40] [41] [42] and HIV-1-infected autologous CD4 þ primary T cells [31] . Accordingly, we observed that NK cell CD107a degranulation and IFNg cytokine production in response to K562 tumor cells was dramatically increased in the presence of IFNa stimulation, particularly among controllers possessing a protective KIR3DL1 Ã h/ Ã y genotype along with their corresponding HLA-Bw4 Ã 80I ligand (Fig. 1c ). The enhanced functional output of NK cells from controllers possessing a protective KIR3DL1 Ã h/ Ã y receptor genotype along with their corresponding HLA-Bw4 Ã 80I ligand was also observed in unstimulated PBMCs, but the effect was not statistically significant ( Fig. 1b) as has been described previously [43] . These findings may suggest that an enhanced ability to respond to IFNa stimulation from plasmacytoid dendritic cell (PDC) may be associated with the NK stimulatory effect observed in individuals inheriting the KIR3DL1 Ã h/ Ã y genotype. Further studies will be needed to conclude if both constitutive levels of NK lysis and IFNa-stimulated NK lysis are simultaneously increased in individuals inheriting the KIR3DL1 Ã h/ Ã y genotype. Our analysis of PDC frequency and Toll-like receptor 9-stimulated PDC secretion of IFNa in individuals from our cohort is consistent with recent data [44] , showing that PDC responses are maintained among controllers (data not shown).
Genetically, we observed that Gag-specific CD8 þ T-cell responses were not significantly different between performed using an unpaired, nonparametric Mann-Whitney t-test and correlations between two variables were carried out using a nonparametric Spearman test. In all cases, P values were two-tailed with a 95% confidence interval. controllers possessing or lacking protective HLA-B alleles (Fig. 2b) . Future work will be needed to address whether protective HLA alleles have an effect on the magnitude of HIV-1-specific Gag responses, as we did not measure the effect of protective HLA alleles on the breadth or polyfunctionality of Gag-specific CD8 þ T-cell responses. In contrast, we confirmed that inheritance of protective KIR3DL1 Ã h/ Ã y genotype along with their corresponding HLA-Bw4 Ã 80I ligand among controllers is associated with significantly increased NK function following IFNa stimulation (Fig. 1c ) when compared with controllers lacking either the protective KIR3DL1 Ã h/ Ã y genotype or the requisite HLA-Bw4 Ã 80I ligands ( Supplementary  Figure 1 , http://links.lww.com/QAD/A248). The protective HLA-B Ã 57 allele, in addition to presenting peptides that are better able to limit viral replication [45] , also serves as a primary ligand for the NK KIR3DL1 receptor. As compared with other HLA-Bw4 Ã 80I ligands, HLA-B Ã 57 has been observed to independently augment NK function [19] . Here, we could not assess the independent effect of HLA-B Ã 57 compared with other HLA-Bw4 Ã 80I ligands on NK function due to the pronounced enrichment of controllers inheriting both the KIR3DL1 Ã h/ Ã y genotype with HLA-B Ã 57 (data not shown). The strong co-inheritance pattern of protective KIR3DL1 Ã h/ Ã y genotype with HLA-B Ã 57 in our cohort of controllers suggests that a synergistic response between the adaptive and innate immune compartment may work in concert to limit viral replication. Although our studies have relied on the universally recognized K562 target cell system to measure NK cytotoxic function, it will be of interest to confirm whether autologous CD4 þ T cells from elite controllers super-infected with HIV-1 are lysed by IFNastimulated NK cells irrespective of low HIV-specific CD8 þ T-cell responses as indicated by our results with K562 cells.
In support of a role for NK pressure in limiting HIV-1 replication, recent data from several groups have identified specific HIV-1 viral escape mutations from CTL responses that can also modulate NK recognition of virally infected cells [46, 47] . Future studies may need to focus on a combination of potential innate and adaptive immune factors to fully elucidate what dominant variables allow for continued elite controller status over time in this rare subset of HIV-1-infected individuals. As elite controllers have been seen as a model for achieving a functional cure in HIV-1-infected individuals [48] , these findings underscore the premise that activation of either innate or adaptive mechanisms of host-mediated control may be associated with control of viral replication in the absence of antiretroviral therapy.
